Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
Rhea-AI Summary
Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 data for TTI-109, a phosphate prodrug of STAT3 inhibitor TTI-101. TTI-109 showed rapid conversion to TTI-101, near-identical exposure at molar-equivalent doses, stable 21-day pharmacokinetics and up to 60% reductions in STAT3-driven Th17, Tfh and B cell populations.
Diarrhea duration was shorter with TTI-109 than TTI-101 (0.46 vs. 3.35 days). Tvardi plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, subject to additional funding and IND clearance.
Positive
- TTI-109 rapidly converted to TTI-101 within two hours, confirming prodrug design
- Near-identical TTI-101 plasma exposure at molar-equivalent doses of TTI-109 and TTI-101
- 21-day repeat dosing showed stable, dose-proportional pharmacokinetics above STAT3 IC₅₀
- Exploratory data showed up to 60% reduction in STAT3-driven Th17, Tfh and B cell subsets
- Diarrhea duration shorter for TTI-109 versus TTI-101 (0.46 vs. 3.35 days)
- Company plans to advance TTI-109 into STAT3-driven dermatologic and GI diseases
Negative
- Advancing TTI-109 programs depends on clearance of an IND application
- Future TTI-109 development is subject to availability of additional funding
Market reaction after Phase 1 TTI-109 clinical data: TVRD +54.23% in the Jul 7 session
In the Jul 7 session, TVRD gained 54.23%, reflecting a significant positive market reaction. Argus tracked a peak move of +168.1% during that session. Our momentum scanner triggered 139 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 139.7x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Phase 2 IPF data | Neutral | +8.7% | Additional REVERT IPF analyses after study overall did not meet goals |
| Oct 13 | Phase 2 IPF miss | Negative | -83.9% | Preliminary REVERT IPF data showing study failed to meet primary goals |
| May 27 | IPF trial enrollment | Positive | +14.8% | Completion of enrollment in Phase 2 REVERT IPF trial of TTI-101 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinical-trial headlines have produced large but directionally mixed moves, with outcomes often aligning closely to the perceived data quality.
Key Terms
stat3 medical
prodrug medical
pharmacokinetics medical
pharmacodynamic medical
investigational new drug application (ind) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells
Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding
Company to host investor webcast today, July 7th, at 8:30am ET
HOUSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor. TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability while preserving the parent compound's mechanism of action. The study confirmed rapid prodrug conversion, dose-proportional pharmacokinetics with exposures above the STAT3 IC₅₀1 and, in an exploratory pharmacodynamic analysis, reductions of up to
Key findings include:
- Confirmed prodrug conversion and exposure equivalence: Validating its prodrug design, TTI-109 rapidly converted to TTI-101 within two hours and produced nearly identical plasma levels at molar-equivalent doses.
- Sustained target-level exposure: 21-day repeat dosing showed stable, dose-proportional pharmacokinetics, with TTI-101 concentrations above the STAT3 IC₅₀.
- Evidence of target engagement: Pharmacodynamic data showed reductions of up to
60% across disease-relevant STAT3-driven immune cell populations including Th17 cells, Tfh and B cell subsets. - Improved tolerability vs. TTI-101: Compared with placebo, diarrhea events with TTI-109 were similar in duration, transient, and resolved without treatment interruption. Compared with TTI-101 at near-equivalent doses, diarrhea events with TTI-109 were substantially shorter in duration (0.46 vs. 3.35 days).
Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, “These Phase 1 results validate our prodrug strategy on every objective we set out to test. TTI-109 matched TTI-101's exposure at molar-equivalent doses with substantially better tolerability and delivered a pharmacodynamic signal across disease-relevant immune cell populations that we would not typically expect to see in healthy volunteers. That combination of findings supports our development pathway into Phase 2.”
The study was conducted in three parts. Part A was a randomized, double-blind, placebo-controlled single ascending dose study of TTI-109 at four doses (n=8/cohort). Part B was a bioequivalence crossover comparing TTI-101 and TTI-109 in both sequences with a 48-hour washout (n=6/sequence). Part C was a randomized, double-blind, placebo-controlled multiple ascending dose study with 21 days of twice-daily dosing at four doses, plus a TTI-101 reference arm (n=8/cohort).
Primary objectives were to confirm rapid conversion of TTI-109 to TTI-101, demonstrate equivalent exposures at molar-equivalent doses, demonstrate dose-dependent increases in TTI-101 exposure and characterize safety and tolerability versus TTI-101 and placebo. Pharmacodynamic effects were an exploratory objective.
Tvardi Plans to Advance TTI-109 Across Dermatologic and GI Therapeutic Areas
The Company has identified dermatologic and gastrointestinal therapeutic areas with shared STAT3-driven disease biology, specifically the convergence of cytokines, growth factors and Th17 and B cell immune pathways at the STAT3 node. TTI-109 is designed to address both the cellular and humoral components of inflammation and proliferation with a single oral agent. Recent programs in related STAT3-driven indications have validated the underlying biology, but each acts on a single upstream target, while TTI-109 targets STAT3, the downstream node where these pathways converge.
STAT3 sits at the center of the core disease processes in dermatologic and gastrointestinal diseases, including inflammation, proliferation and cellular and humoral dysregulation. Tvardi's STAT3 inhibitors have demonstrated biologic activity in these pathways in both preclinical models and in the clinic. In preclinical disease models, the Company’s STAT3 inhibitors reduced inflammatory cascades, fibrosis and modulated immune activity. Similarly, in humans, TTI-101 reduced activated STAT3 levels, inflammatory cascades and fibrosis. The TTI-109 healthy volunteer study extended this translational profile, with reductions in STAT3-driven immune cell populations.
“The diseases we are targeting are still largely managed with parenteral therapies that each block a single pathway,” said Dr. Alibhai. “Because STAT3 sits downstream of multiple convergent signals, a single oral STAT3 inhibitor has the potential to do what no single-pathway biologic can and we believe our preclinical, clinical and now pharmacodynamic data are building a consistent case that TTI-109 is a promising molecule to test this hypothesis.”
Tvardi's ability to initiate these programs is subject to clearance of an Investigational New Drug application (IND) and the availability of additional funding.
Webcast
Tvardi management will host a webcast today, Tuesday, July 7th, 2026, at 8:30 am ET to discuss these results in more detail.
The webcast can be accessed here: https://lifescievents.com/event/t349t28y/.
About Tvardi Therapeutics
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company has completed a Phase 1 healthy volunteer study of TTI-109 and plans to initiate clinical trials of TTI-109 in dermatologic and GI diseases, pending IND clearance and the availability of additional funding. The company is also conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).
Contacts:
For Tvardi:
Tvardi Investor Relations
ir@tvardi.com
PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com
Cautionary Statement Regarding Forward-looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the anticipated benefits of Tvardi’s product candidates, including TTI-109 in dermatologic and GI therapeutic areas and of the Company’s STAT3 inhibitors, including as compared to single-pathway biologics; the potential benefits of TTI-109 as compared to TTI-101, including improved delivery and tolerability; its ongoing and planned clinical trials, including its ongoing Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma and its planned Phase 2 trials of TTI-109; the results from the Phase 1 trial of TTI-109 validating the Company’s prodrug strategy and supporting its development pathway into Phase 2; the Company’s plans to develop TTI-109 in dermatologic and GI therapeutic areas, subject to clearance of an IND application and receipt of additional funding; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them.
Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks, including, among other things: the uncertainties associated with Tvardi’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials or safety or other complications related to its product candidates; the ability to obtain IND clearance for TTI-109 in dermatologic and GI therapeutic areas on the timelines expected or at all; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; the significant net losses Tvardi has incurred since inception; Tvardi’s ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from Tvardi’s clinical trials; the outcome of preclinical testing and clinical trials of the Tvardi’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; Tvardi’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Tvardi’s product candidates; the estimated patient populations and total addressable markets for the indications in which Tvardi seeks to develop its product candidates; Tvardi’s anticipated cash runway; Tvardi’s ability to attract, hire, and retain skilled executive officers and employees; Tvardi’s ability to protect its intellectual property and proprietary technologies; Tvardi’s reliance on third parties, contract manufacturers and contract research organizations; the possibility that Tvardi may be adversely affected by other economic, business or competitive factors; risks associated with changes in applicable laws or regulations; those factors discussed in Tvardi’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Annual Report on Form 10-K for the year ended December 31, 2025, and Tvardi’s other documents subsequently filed with or furnished to the SEC, all of which are available on the SEC’s website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. The company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
1 In a controlled system where proliferation is driven by WT STAT3, TTI-101 inhibits cell growth with an IC₅₀ of approximately 1.5µM. Kasembeli MM, Kaparos E, Bharadwaj U, et al. Aberrant function of pathogenic STAT3 mutant proteins is linked to altered stability of monomers and homodimers. Blood. 2023;141(12):1411-1424. doi:10.1182/blood.2021015330.
